Japan’s health ministry approved a slew of new medicines on September 25 including multiple “first of its kind” products, among them being GlaxoSmithKline’s respiratory syncytial virus (RSV) vaccine Arexvy as well as Eisai’s Alzheimer’s therapy Leqembi (lecanemab).Arexvy became the first…
HOME > REGULATORY
REGULATORY
- MHLW to Launch Working Group on Drug Supply Info on Sept. 7
September 5, 2023
- 23 Suspected Violations in Promotion Activities Reported in FY2022: MHLW
September 5, 2023
- Dispensing Pharmacy Chief Nabbed for Obstruction of Public Bid
September 4, 2023
- Japan Launches Agency for Infectious Disease Crisis Management
September 4, 2023
- Relief Claims OK’ed for 54 More Deaths after COVID Vaccination
September 4, 2023
- Japan Approves Pfizer’s Omicron XBB.1.5 Vaccine, Moderna’s Still under Review
September 4, 2023
- MHLW Rejigs Organization, Infectious Disease Control Team Boots Up
September 1, 2023
- Industry Requests Rewards for SaMDs that Help Doctors’ Workstyle Reform
September 1, 2023
- Japan to Decide on COVID Health Funding from October, Assuming Shift to Normalcy Next Spring: Minister
September 1, 2023
- MHLW Must Streamline Operations via DX, Improve Staff’s Work-Life Balance: Official
September 1, 2023
- 8 New Cases of Unintentional Xocova Use Among Pregnant Patients, Adding Up to 15
August 31, 2023
- Chuikyo Payer Rep Floats Deferred Price Cuts for PMP upon Generic Entries
August 31, 2023
- MHLW Top Pharma Officer Remains Committed to Fast, Safe Access to Good Drugs
August 31, 2023
- MHLW to Unveil Draft of 2nd Package Strategy for SaMD on Sept. 6
August 31, 2023
- MHLW to Issue Development Requests for New Uses of Rituxan, Truvada, and More
August 31, 2023
- Medical DX Office to Kick Off in September, Explore Better Use of Medical Data for Drug Discovery
August 30, 2023
- MHLW Orders Label Revisions for Prazaxa, Smyraf, and More
August 30, 2023
- MHLW Panel OKs Inclusion of 5-in-1 Vaccine in National Immunization Program
August 30, 2023
- Label Revisions Ordered for CAR-T Therapies on Out-of-Spec Products
August 30, 2023
- Japan Panel Clears GSK’s Arexvy, 1st RSV Vaccine, for Approval
August 29, 2023
ページ
A doctor member of the Central Social Insurance Medical Council (Chuikyo) on September 20 traded barbs with pharma leaders over…
The Ministry of Health, Labor and Welfare (MHLW) on September 19 proposed restructuring the Japanese generic industry by restricting the…
The Ministry of Health, Labor and Welfare (MHLW) plans to no longer require the implementation of additional PI clinical studies…
IntroductionCommercial transformation is a top priority for pharma leaders in Japan and rightfully so. In a market with low single…
In the run-up to FY2024 budget requests this summer, there were growing hopes in the pharmaceutical industry that the government's de-facto cap on increases in social security spending would finally be lifted. That did not happen, despite strong calls from…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…